Kelly, Louise M <br/><br/>
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).  [electronic resource] 

 -  Cancer cell  Jun 2002 
 - 421-32 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1535-6108 
<br/><br/><label>Standard No.: </label>10.1016/s1535-6108(02)00070-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Bone Marrow Cells--enzymology<br/>Bone Marrow Transplantation<br/>Enzyme Inhibitors--pharmacology<br/>Flow Cytometry<br/>Humans<br/>Immunoblotting<br/>Interleukin-3--metabolism<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Mutation<br/>Phosphorylation<br/>Piperazines--pharmacology<br/>Proto-Oncogene Proteins--antagonists & inhibitors<br/>Proto-Oncogene Proteins c-kit--drug effects<br/>Quinazolines--pharmacology<br/>Receptor Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Receptors, Cell Surface--antagonists & inhibitors<br/>Receptors, Platelet-Derived Growth Factor--antagonists & inhibitors<br/>Tandem Repeat Sequences<br/>Transfection<br/>Tumor Cells, Cultured--drug effects<br/>fms-Like Tyrosine Kinase 3